Cargando…

Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma

The t(11;14)/CCND1‐IGH, t(4;14)/NSD2(MMSET)‐IGH, and t(14;16)/IGH‐MAF gene rearrangements detected by fluorescence in situ hybridization (FISH) are used for risk stratification in patients with multiple myeloma (MM). Compared with conventional FISH techniques using fresh cells, immunohistochemistry...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murase, Takayuki, Ri, Masaki, Narita, Tomoko, Fujii, Keiichiro, Masaki, Ayako, Iida, Shinsuke, Inagaki, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676137/ https://www.ncbi.nlm.nih.gov/pubmed/31218784 http://dx.doi.org/10.1111/cas.14109

Ejemplares similares

Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system
por: Murase, Takayuki, et al.
Publicado: (2019)

Immunohistochemistry for CCR4 C‐terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T‐cell leukemia/lymphoma
por: Fujii, Keiichiro, et al.
Publicado: (2020)

Case report: Genomic analysis of a therapy-related chronic myelomonocytic leukemia with KMT2A rearrangement that progressed to acute myeloid leukemia with acute promyelocytic leukemia-like features
por: Suzuki, Tomotaka, et al.
Publicado: (2023)

P820: POTENTIAL IMMUNOSUPPRESSIVE EFFECT OF EXTRACELLULAR VESICLES FROM PATIENTS WITH MULTIPLE MYELOMA
por: Hagiwara, Shinya, et al.
Publicado: (2023)

Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals
por: Masaki, Ayako, et al.
Publicado: (2018)

PB1962: COMPARISON OF EXPRESSION OF NSD2, CYCLIN D1 AND C-MAF BY PLASMA CELLS IN BONE MARROW AND BONE PLASMACYTOMA IN PATIENTS WITH PLASMA CELL MYELOMA
por: Mamaeva, E., et al.
Publicado: (2022)

Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma
por: Yoshida, Takashi, et al.
Publicado: (2018)

Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits
por: Yoshida, Takashi, et al.
Publicado: (2018)

Clinical significance of tryptophan catabolism in Hodgkin lymphoma
por: Masaki, Ayako, et al.
Publicado: (2017)

Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma
por: Kinoshita, Shiori, et al.
Publicado: (2018)

Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy
por: Kikuchi, Takaki, et al.
Publicado: (2020)

Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy
por: Narita, T, et al.
Publicado: (2015)

Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma
por: Maekawa, Keiko, et al.
Publicado: (2019)

In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L
por: Morishita, Masayo, et al.
Publicado: (2014)

Anaplastic multiple myeloma with amplification of the IGH-CCND1 gene fusion
por: Alencar, Rafael Nobrega, et al.
Publicado: (2023)

Achromobacter Infection Is Rare in Japanese Patients with Pulmonary B-cell Lymphoma
por: Aoyama, Satsuki, et al.
Publicado: (2017)

MYC Immunohistochemistry Predicts MYC Rearrangements by FISH
por: Nwanze, Julum, et al.
Publicado: (2017)

Volunteer unrelated donor cell‐derived acute myeloid leukemia with RUNX1‐RUNX1T1
por: Hagiwara, Shinya, et al.
Publicado: (2021)

Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis
por: Gameiro, Steven F., et al.
Publicado: (2021)

TM-233, a novel analog of 1′-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities
por: Sagawa, Morihiko, et al.
Publicado: (2015)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Clinical significance of TP53 mutations in adult T‐cell leukemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2021)

CCND1 Genomic Rearrangement as a Secondary Event in High Grade B-Cell Lymphoma
por: Cheng, Jinjun, et al.
Publicado: (2020)

A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma
por: Ri, Masaki, et al.
Publicado: (2017)

MafA Is Required for Postnatal Proliferation of Pancreatic β-Cells
por: Eto, Koki, et al.
Publicado: (2014)

NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis
por: Peri, Suraj, et al.
Publicado: (2017)

CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment
por: Sakamoto, Yuma, et al.
Publicado: (2022)

Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells
por: WADA, NAOKO, et al.
Publicado: (2014)

Case report: Identification of atypical mantle cell lymphoma with CCND3 rearrangement by next-generation sequencing
por: Dai, Luomengjia, et al.
Publicado: (2023)

MiR-181a functions as an oncogene by regulating CCND1 in multiple myeloma
por: Yan, Xiao, et al.
Publicado: (2020)

NSD1 in erythroid differentiation and leukemogenesis
por: Tauchmann, Samantha, et al.
Publicado: (2020)

GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target
por: Herath, N I, et al.
Publicado: (2014)

Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
por: Wei, GuoQing, et al.
Publicado: (2017)

Loss of MafA and MafB expression promotes islet inflammation
por: Singh, Tania, et al.
Publicado: (2019)

Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR
por: Takezako, Naoki, et al.
Publicado: (2020)

Posttranslational modification of Aurora A‐NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma
por: Jiang, Hongmei, et al.
Publicado: (2022)

Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry
por: Firsova, Maiia V., et al.
Publicado: (2020)

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan
por: Suzuki, Kenshi, et al.
Publicado: (2017)

Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis
por: Wang, Siyu, et al.
Publicado: (2017)

Inhibition of the Otub1/c-Maf axis by the herbal acevaltrate induces myeloma cell apoptosis
por: Sun, Tong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6hejjlg8dqn7gc8cuf8masaars